The therapeutic targets session follows at 14:30, with Lepore moderating. Ann Hellström will present primary outcomes of DROPROP, a study of dexamethasone for prethreshold ROP, along with implications for practice.2 Moshfeghi will discuss the tROPhy study of lipid peroxidation inhibition for ROP prevention, and Lepore will give an anti-VEGF update covering aflibercept, bevacizumab, and ranibizumab.2
Nimesh Patel will close the session with data on eventual treatment rates in stage 2 and type 2 ROP.2 Later Friday sessions address international ROP care, including screening networks in low- and middle-income countries, and risk ascertainment, including genetic testing and the biology of fibrosis.2 The day ends with ROP Miscellany I, where Lepore will address ROP myopia and Campbell will discuss emerging pathologies in adult ROP.2
Key Insights for retinal specialists
- FLO-ROP runs 4 and 5 December 2026 within FLORetina-ICOOR, coordinated by Darius M. Moshfeghi, MD, and Domenico Lepore, MD.
- Day 1 features DROPROP dexamethasone primary outcomes, the tROPhy lipid peroxidation study, and an anti-VEGF update.
- Day 2 covers pediatric vitreoretinal surgery and Stickler syndrome, plus panels on ROP treatment criteria and peripheral avascular retina.
Pediatric vitreoretinal surgery and ROP treatment criteria debates on day 2
Saturday, 5 December shifts toward surgical and complex pediatric disease. A Stickler syndrome session includes talks on genetics and prophylaxis, prevention of retinal detachment, ultra-widefield OCT, and management of primary treatment failures.2 A session on pediatric vitreoretinal surgery approaches follows, with presentations on scleral buckling in pediatric retinal detachment and methotrexate for pediatric proliferative vitreoretinopathy.2
ROP Miscellany II, moderated by Audina M. Berrocal, MD, Moshfeghi, and Georges Caputo, includes BabySTEPS data from Toth on retinal nerve fiber layer thickness and neurodevelopmental outcomes in very preterm infants.2 Other talks address progressive myopia as a sequela of ROP and medical malpractice risk in ROP care.2 Three panel discussions will examine anti-VEGF and ROP treatment criteria, peripheral avascular retina management, and fibrosis in the ROP diagnostic rubric.2
A pediatric retina miscellany session covers familial exudative vitreoretinopathy, persistent fetal vasculature, Coats disease, and gene therapy challenges in children.2 The day concludes in the same room with "ROP in Question: Where Evidence Meets Experience," a rapid-format session organized by Fiammetta Catania.2 Its talks address personalized surveillance, AI and plus disease, first-line treatment choice, and retreatment of persistent avascular retina.2
The DROPROP primary outcomes and the tROPhy presentation are the pathway's clearest trial readouts to watch, alongside Lepore's anti-VEGF update.2 Together, the sessions span pharmacologic prevention, screening technology, and surgical management across the pediatric retina spectrum.
References
FLORetina-ICOOR 2026. Programme. FLORetina ICOOR Meeting. Accessed November 2, 2026. https://floretinaicoormeeting.com/programme
FLORetina-ICOOR Meeting 2026 preliminary program (updated October 23, 2026). FLORetina ICOOR Meeting. Accessed November 2, 2026. https://floretinaicoormeeting.com/programme/pdf